CN115697996A - 烯基嘧啶类化合物、其制备方法与应用 - Google Patents

烯基嘧啶类化合物、其制备方法与应用 Download PDF

Info

Publication number
CN115697996A
CN115697996A CN202180041038.1A CN202180041038A CN115697996A CN 115697996 A CN115697996 A CN 115697996A CN 202180041038 A CN202180041038 A CN 202180041038A CN 115697996 A CN115697996 A CN 115697996A
Authority
CN
China
Prior art keywords
piperidinyl
methyl
pyrazolyl
formyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041038.1A
Other languages
English (en)
Inventor
邓贤明
黄伟
吴振华
吴亚闯
云彩红
张建明
黄鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Hongyun Bio Tech Co ltd
Original Assignee
Nanjing Hongyun Bio Tech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Hongyun Bio Tech Co ltd filed Critical Nanjing Hongyun Bio Tech Co ltd
Publication of CN115697996A publication Critical patent/CN115697996A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

本发明涉及烯基嘧啶类化合物、其制备方法与应用，具体地，涉及具有EGFR抑制活性化合物及其药学上可接受的盐或药学上可接受的溶剂合物，其制备方法、包含该化合物的药物组合物，以及这些化合物在制备用于EGFR激酶介导的癌症及其他疾病的预防和/或治疗的药物的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180041038.1A 2020-06-08 2021-06-07 烯基嘧啶类化合物、其制备方法与应用 Pending CN115697996A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020105103457 2020-06-08
CN202010510345 2020-06-08
CN202110590788 2021-05-28
CN2021105907886 2021-05-28
PCT/CN2021/098539 WO2021249324A1 (zh) 2020-06-08 2021-06-07 烯基嘧啶类化合物、其制备方法与应用

Publications (1)

Publication Number Publication Date
CN115697996A true CN115697996A (zh) 2023-02-03

Family

ID=78845318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041038.1A Pending CN115697996A (zh) 2020-06-08 2021-06-07 烯基嘧啶类化合物、其制备方法与应用

Country Status (13)

Country Link
US (1) US20230212147A1 (zh)
EP (1) EP4166553A1 (zh)
JP (1) JP2023528170A (zh)
KR (1) KR20230022976A (zh)
CN (1) CN115697996A (zh)
AU (1) AU2021288300A1 (zh)
BR (1) BR112022024937A2 (zh)
CA (1) CA3186484A1 (zh)
CL (1) CL2022003477A1 (zh)
IL (1) IL298864A (zh)
MX (1) MX2022015659A (zh)
TW (1) TW202214590A (zh)
WO (1) WO2021249324A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116438172A (zh) * 2020-11-13 2023-07-14 南京红云生物科技有限公司 Hpk1激酶调节剂、其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
MX2020000710A (es) * 2017-07-19 2020-07-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto de aril-fósforo-oxígeno como inhibidor de la cinasa del egfr.
CN109575045B (zh) * 2017-09-28 2021-02-12 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN113166103B (zh) * 2019-04-26 2022-12-16 江苏先声药业有限公司 Egfr抑制剂及其应用
CN112538072B (zh) * 2019-09-21 2024-02-06 齐鲁制药有限公司 氨基嘧啶类egfr抑制剂

Also Published As

Publication number Publication date
AU2021288300A1 (en) 2023-02-02
CA3186484A1 (en) 2021-12-16
MX2022015659A (es) 2023-02-27
KR20230022976A (ko) 2023-02-16
JP2023528170A (ja) 2023-07-04
BR112022024937A2 (pt) 2022-12-27
US20230212147A1 (en) 2023-07-06
CL2022003477A1 (es) 2023-08-25
EP4166553A1 (en) 2023-04-19
IL298864A (en) 2023-02-01
TW202214590A (zh) 2022-04-16
WO2021249324A1 (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
ES2753386T3 (es) Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
EP3626718B1 (en) Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
KR102429355B1 (ko) 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도
JP7050093B2 (ja) 置換５員および６員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
KR20020093086A (ko) 축합 헤테로아릴 유도체
CN110770234B (zh) 取代芳基醚类化合物、其制备方法、药用组合物及其应用
WO2018210296A1 (zh) 一种ezh2抑制剂与btk抑制剂联合在制备***的药物中的用途
CN114656482A (zh) 作为egfr抑制剂的大环杂环类化合物及其应用
CN109575045B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
KR20210122861A (ko) 이미다조피리디닐 화합물 및 증식성 질환의 치료를 위한 그의 용도
AU2020342189A1 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
CN115697996A (zh) 烯基嘧啶类化合物、其制备方法与应用
WO2019085978A1 (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CA3090876C (en) Dioxinoquinoline compounds, preparation method and uses thereof
JP7165501B2 (ja) 新規ベンズイミダゾール化合物からなる医薬
CN115916759A (zh) 取代喹唑啉类化合物、其制备方法、药物组合及应用
CN117794923A (zh) 苯并二噁烷类化合物、其制备方法与应用
CN116981662A (zh) 嘧啶-4，6-二胺衍生物及其制备方法和药学上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079301

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination